Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue

Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.

Scientist analyzes DNA gel used in genetics, forensics, drug discovery, biology and medicine.
Genomics and proteomics are helping Amgen R&D work more efficiently • Source: Shutterstock

Amgen Inc. has been working for years to improve the efficiency of its research and development group, but executive vice president of R&D David Reese said that when he moved into his role 18 months ago he looked at additional ways to streamline the organization so that it works within an industry business model that’s changing based on increasing concerns about the costs of new drugs.

“What I really did was take a basic approach and say, 'OK, what are our assumptions about the world over...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip